Background The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may
initiate or potentiate pathologic processes in Alzheimer's disease. Lecanemab, a humanized …

Objective We performed a systematic review and meta-analysis of the cognitive
effectiveness and safety of lecanemab on subjects with Alzheimer's disease (AD). Methods …

Lecanemab (lecanemab-irmb; LEQEMBI™) is a humanized immunoglobulin gamma 1
(IgG1) against aggregated soluble and insoluble forms of amyloid-β peptide. It is being …

Abstract Background Lecanemab, a humanized IgG1 monoclonal antibody that targets
soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid …

Abstract Background Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially
targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and …

Abstract On July 6, 2023, the US Food and Drug Administration (FDA) approved lecanemab
(Leqembi) for the treatment of Alzheimer's dementia (AD) patients. In 2 clinical trials …

Background Lecanemab (BAN2401) is a humanized IgG1 monoclonal antibody that
preferentially targets soluble aggregated Aβ species (protofibrils) with activity at insoluble …

The phase III Clarity AD clinical trial of lecanemab, an amyloid-targeting antibody, showed a
small clinical benefit in people with Alzheimer disease. However, several questions remain …

The agency granted lecanemab conditional approval in January through its accelerated
approval pathway—which allows drugs onto the market before efficacy has been proved …

Lecanemab, a novel amyloid-sequestering agent, recently received accelerated Food and
Drug Administration approval for the treatment of mild dementia due to Alzheimer disease …